Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas Logs Sales Growth in Q1, but Profits Drop Sharply on Write-Offs
August 2, 2021
- Takeda’s Q1 Sales Rise on Diabetes Divestiture; Plant Re-Inspection Results Expected Late October
August 2, 2021
- PeptiDream, Alnylam Collaborate to Discover and Develop Peptide-siRNA Conjugates
August 2, 2021
- Biogen, Eisai Reveal Real-World Study Design of Aducanumab
August 2, 2021
- Ono’s Q1 Sales Up 16.6% on Opdivo Indication Expansions
August 2, 2021
- Nicholas Jones Named New Biogen Japan President
August 2, 2021
- Takeda, American VC Forge New Company to Develop Norovirus Vaccine
August 2, 2021
- Sumitomo Dainippon’s Q1 Sales Skid 2.0% on Lower Latuda Revenue
July 30, 2021
- Takeda’s Narcolepsy Drug Snags FDA’s Breakthrough Therapy Tag
July 30, 2021
- Tissue-Engineering Market in 5 Asian Areas to Approach 700 Billion Yen in 2030: Fuji Keizai
July 30, 2021
- Pfizer Japan Recalling Some Champix Products after Detecting Carcinogen
July 29, 2021
- Toray, Veritas Tie Up to Discover Small Molecule Drugs Targeting mRNA
July 29, 2021
- Shionogi in Talks with Vietnam Govt on Vaccine Tech Transfer
July 29, 2021
- European Panel Rejects Kyowa Kirin’s Parkinson’s Med
July 29, 2021
- Kyowa Kirin Files Bardoxolone Methyl in Japan for Alport Syndrome
July 29, 2021
- Ayumi Adjusts Shipments for RA Med Rimatil Impacted by Peers' Unstable Supplies
July 29, 2021
- Towa’s Shipment Curbs Now Affect 319 Products, Active Vitamin Analogs Too
July 29, 2021
- Keytruda Keeps Top Drug Crown in FY2020 despite Double-Digit Dip: Tally
July 28, 2021
- MSD Urges Expansion of Exclusion Criteria for Spillover Rules as Repeated Cuts Hit Keytruda
July 28, 2021
- Meiji to Sell JV Stake to Dong-A, but Will Continue Biosimilar Collaboration
July 28, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…